Andrew Seidman, MD, and Hope Rugo, MD, on Advanced Breast Cancer: KEYNOTE-028 Study Results

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor-positive/HER2-negative disease. (Abstract S5-07)

Related Videos

Breast Cancer

Symptom Management

Andrew Seidman, MD, and Hope S. Rugo, MD

Andrew Seidman, MD, and Hope Rugo, MD, on Reducing Alopecia: FDA Approves New Device

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss the recent approval of...

Breast Cancer

Lisa A. Carey, MD, and Kathy S. Albain, MD

Lisa Carey, MD, and Kathy Albain, MD, on Results of the SWOG-8814 Trial

Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on ad...

Breast Cancer

Hans Wildiers, MD, PhD

Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results

Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously...

Breast Cancer

Patricia A. Ganz, MD

Patricia Ganz, MD, on Results from NSABP B-35: Patient-Reported Outcomes

Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in sit...

Breast Cancer

Andrew Seidman, MD, and Ruth M. O’Regan, MD

Andrew Seidman, MD, and Ruth O'Regan, MD: Update on Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Ruth M. O’Regan, MD, of the University of Wisconsin, review practice-changing research in 2015 t...